Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings
KRYS·Reported May 6, 2024·Before market open
Krystal Biotech, Inc. reported Q1 2024 revenue of $45.3M, missed analyst consensus of $47.4M by $2.2M. Diluted EPS came in at $0.03, missed the $0.15 consensus by $0.12.
Revenue
$45.3Mmissed by $2.2M
Consensus: $47.4MDiluted EPS
$0.03missed by $0.12
Consensus: $0.15
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Krystal Biotech, Inc.'s Q1 2024 earnings report.
Krystal Biotech, Inc. (KRYS) reported Q1 2024 earnings on May 6, 2024 before market open.
Krystal Biotech, Inc. reported revenue of $45.3M and diluted EPS of $0.03 for Q1 2024.
Revenue missed the consensus estimate of $47.4M by $2.2M. EPS missed the consensus estimate of $0.15 by $0.12.
You can read the 10-Q periodic report (0001711279-24-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.